Bumpus Namandje sold $16K of RXRX
Bumpus Namandje sold 4,386 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.54 on 2026-06-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides incremental information about insider liquidity, but does not, by itself, change Recursion’s fundamentals or near-term catalysts.
Market read
A single director sale at a specific price is unlikely to drive a durable repricing absent other company news.
What to watch
Traders may over-weight Form 4 prints; without accompanying news (trial, financing, guidance), the signal-to-noise is low.
Background
SEC Form 4 reports insider transactions; this one is a director open-market sale executed under a pre-arranged 10b5-1 plan.
Ticker impact
Recursion Pharmaceuticals disclosed a director open-market sale of 4,386 shares at $3.54 under a pre-arranged 10b5-1 plan.
Low likelihood of sustained price impact; any reaction is likely muted and short-lived.
The filing is an ownership-change disclosure (Form 4) with a stated pre-arranged 10b5-1 plan, which reduces interpretability versus discretionary selling.
Market effects
Minimal; this is company-specific insider activity with no stated operational/regulatory/clinical linkage.
None indicated.
None indicated.
Counterpoint
Because the sale is pre-arranged under 10b5-1, it can reflect routine liquidity rather than bearish expectations; price may ignore it.
Key entities
- issuerRecursion Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure.
- directorBumpus Namandje
Director who sold shares under a pre-arranged 10b5-1 plan.
